REMINDER: Our user survey closes on Friday, please submit your responses here.
I would like to remind people how long it took from the RNS stating we were on Activ2 to when it appeared on the NIH website.
As I recall, we waited and waited for an announcement or for Fauci to make reference to us in his regular press briefing but it was many weeks before our inclusion in Activ2 became official.
As I said before, it is likely that Synairgen have been give a slap on their wrist for the timing of their RNS. With so much at stake, they are not going cross NIH anytime soon by announcing phase 3 prematurely .
Pulse article from April 21 seems to support prescription of budesonide on a case by case basis
https://www.pulsetoday.co.uk/news/clinical-areas/respiratory/gps-can-prescribe-asthma-medicine-off-label-to-treat-covid-says-uk-drugs-regulator/
However, article from EMA on 27/5/21 takes a different view:
"insufficient evidence that inhaled corticosteroids are beneficial for people with COVID-19.
Although the taskforce found no safety risks from studies so far, it could not exclude the possibility of harm from the use of inhaled corticosteroids in patients with COVID-19 who have normal levels of oxygen."
SOURCE https://www.ema.europa.eu/en/news/insufficient-data-use-inhaled-corticosteroids-treat-covid-19
Daily Mail and Daily Telegraph - poor journalism again.
Yes.
https://www.lsegissuerservices.com/spark/Synairgen/events/1cd87eb6-5e01-4e1a-b3bd-f8288bbb6b5b
Yes, Activ2 is the USA's baby, not Synairgen's, so the BOD can't make any comment about advancement.
I wonder if the BOD got a slap on the wrist when they announced our inclusion in Activ2 back at the start of the year. Remember how long it took before it was officially recorded on the Activ2 website.
Put two chartist in the same room and we are likely to agree and disagree! ;-)
Essentially 6 and half a dozen.
Given the recent strengths, I would put the low support level at 137 (9 June). If price should reverse and take out 137, then the next support is from 25 May at 119.
My Fib numbers are initial projections. A very strong RNS will just blow through these numbers. Conversely a so-so RNS might see price hang around these Fib levels for a little while, perhaps even bouncing between them.
These numbers are levels or zones, not exact price points, though I have seen market prices reach exact Fib numbers and turn on a dime. That's likely because many investors/traders use Fib numbers as a guide too.
@Denny and @ Tommo
That is also my understanding of the effectiveness of the vaccines.
These vaccines are NOT like the vaccine for small pox which aimed to eradicate small pox. These vaccines do not stop Covid19 infection (compare with the common cold - a lost cause), but to reduce infection rates and if infected, reduce the severity and therefore the demand on hospital beds.
Another thing I understand about these vaccines is that effectiveness will wane over time so a booster is required over the latter end of this year.
On a related issue, because of the dominance of the Covid19 virus, there is concern that scientists do not know how to predict which variant of the annual flu will appear this winter. It is very possible that the flu vaccine (normally given in the winter months) will be combined with the Covid19 vaccine booster. If they predict and vaccinate against the wrong flu variants, we may see an increase in deaths and complications from flu this winter.
On the other hand, SNG001 will work to alleviate breathlessness from flu or Covid19!
Stockpile against future corona viruses!
https://edition.cnn.com/2021/06/10/health/bats-coronavirus-china-genome/index.html
@PErsimmon
Please do not give any credit to the orange man - hundreds of thousands have died under his watch. His purpose is always to self-promote, sow chaos, discord and division. His choice of words, Chinese Flu, only seeks to inflame and divide, causing even more racial tension and harm to the innocent.
The orange man said/says a lot of things - but even a broken clock is right twice in a day.
Thanks Dafad.
Though we are still awaiting the ground-breaking results from the trials, what is clear, is that interferons are no longer taking a back seat. How often in the past year, had we seen promising media coverage of interferons sidelined as an after thought or battling against the negativity of the WHO intravenous trial.
Now interferon listed as 2nd in the list of promising trials - coming out from the UK (not France ;-)!
Who-hoo!